Innovative Pipeline Airway Therapeutics is advancing a promising pipeline with its lead candidate AT-100, targeting severe neonatal respiratory diseases such as bronchopulmonary dysplasia and COVID-19, presenting opportunities for specialized biotech suppliers and collaborators in pediatric and respiratory therapeutics.

Recognition & Awards Winning the 2024 ATS Whitsett Award highlights the company's recognition in the respiratory research community, which can facilitate partnerships with academic institutions, research organizations, and pharmaceutical companies interested in licensed or co-developed respiratory treatments.

Funding & Growth With $16 million in funding and early-stage revenue, Airway Therapeutics is positioned for clinical development and manufacturing expansion, offering sales opportunities in biotech manufacturing services, clinical trial support, and early-stage pharma collaborations.

Strategic Collaborations Collaborations with CMO Celonic Group and recent executive hires demonstrate a focus on building a strong operational infrastructure, opening doors for vendors supplying biomanufacturing, regulatory compliance, and clinical development solutions.

Focus on Respiratory Disease The company’s focus on innovative biologics for respiratory and inflammatory diseases creates a niche market for medical device companies, clinical research firms, and biotech partners interested in expanding their portfolio into neonatal and inflammatory disease markets.